Emerging and Alternative Therapies For Parkinson Disease: An Updated Review.
Identifieur interne : 000829 ( Main/Exploration ); précédent : 000828; suivant : 000830Emerging and Alternative Therapies For Parkinson Disease: An Updated Review.
Auteurs : Atul Kabra [Inde] ; Rohit Sharma [Inde] ; Ruchika Kabra [Inde] ; Uttam Singh Baghel [Inde]Source :
- Current pharmaceutical design [ 1873-4286 ] ; 2018.
Descripteurs français
- KwdFr :
- MESH :
- composition chimique : Antiparkinsoniens.
- méthodes : Thérapies complémentaires.
- thérapie : Maladie de Parkinson.
- usage thérapeutique : Antiparkinsoniens.
- Humains, Procédures de neurochirurgie.
English descriptors
- KwdEn :
- MESH :
- chemical , chemistry : Antiparkinson Agents.
- chemical , therapeutic use : Antiparkinson Agents.
- methods : Complementary Therapies.
- therapy : Parkinson Disease.
- Humans, Neurosurgical Procedures.
Abstract
Parkinson's disease (PD) is standout amongst the most common neurodegenerative malady with unpredictable dynamic pathology. At present, accessible traditional choices for PD have certain impediments of their own, and subsequently persistent consistence and fulfillment are low. Current contemporary treatment options just give symptomatic alleviation constrained control to anticipate malady progression, bringing about poor patient consistence and fulfilment. Numerous rising pharmacotherapies for PD are in various phases of medical improvement. Treatments incorporate adenosine A2A receptor antagonists, anti-apoptotic agents, monoamine oxidase inhibitors, glutamate receptor antagonists, and antioxidants for example, N-acetyl cysteine, edaravone, and coenzyme Q10. Other rising nonpharmacotherapies incorporate microRNAs, viral vector gene therapy, stem cells transglutaminases, RTP801, and glial derived neurotrophic factor (GDNF). Furthermore, surgeries including profound pallidotomy, deep brain stimulation, thalamotomy and gamma knife surgery have developed as elective mediations for cutting edge PD patients who have totally used common medications and still suffer from unrelenting motor symptoms. Complementary and Alternative medicine (CAM) modalities, such as Yoga, acupuncture, Tai Chi, Music therapies are highly practiced in several countries, offer some of the safer and effective treatment modalities for PD. While a few of these treatments hold much assurance in postponing the beginning of ailment and moderating its progression, more pharmacotherapies and careful mediations should be examined in various phases of PD. Therefore, the main objective of our review is to fill the gap between the researches and provide updated and productive information about the research reported in the last couple of years and can fulfil the most reassuring plausibility for encourage treatment of Parkinson Disease.
DOI: 10.2174/1381612824666180820150150
PubMed: 30124146
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Emerging and Alternative Therapies For Parkinson Disease: An Updated Review.</title><author><name sortKey="Kabra, Atul" sort="Kabra, Atul" uniqKey="Kabra A" first="Atul" last="Kabra">Atul Kabra</name><affiliation wicri:level="1"><nlm:affiliation>I.K. Gujral Punjab Technical University, Kapurthala, Punjab, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>I.K. Gujral Punjab Technical University, Kapurthala, Punjab</wicri:regionArea><wicri:noRegion>Punjab</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Kota College of Pharmacy, Kota, Rajasthan, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Kota College of Pharmacy, Kota, Rajasthan</wicri:regionArea><wicri:noRegion>Rajasthan</wicri:noRegion></affiliation></author><author><name sortKey="Sharma, Rohit" sort="Sharma, Rohit" uniqKey="Sharma R" first="Rohit" last="Sharma">Rohit Sharma</name><affiliation wicri:level="1"><nlm:affiliation>Central Ayurveda Research Institute for Drug Development, CCRAS, Ministry of AYUSH, Government of India, Bidhannagar, Kolkata, West Bengal, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Central Ayurveda Research Institute for Drug Development, CCRAS, Ministry of AYUSH, Government of India, Bidhannagar, Kolkata, West Bengal</wicri:regionArea><wicri:noRegion>West Bengal</wicri:noRegion></affiliation></author><author><name sortKey="Kabra, Ruchika" sort="Kabra, Ruchika" uniqKey="Kabra R" first="Ruchika" last="Kabra">Ruchika Kabra</name><affiliation wicri:level="1"><nlm:affiliation>Kota College of Pharmacy, Kota, Rajasthan, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Kota College of Pharmacy, Kota, Rajasthan</wicri:regionArea><wicri:noRegion>Rajasthan</wicri:noRegion></affiliation></author><author><name sortKey="Baghel, Uttam Singh" sort="Baghel, Uttam Singh" uniqKey="Baghel U" first="Uttam Singh" last="Baghel">Uttam Singh Baghel</name><affiliation wicri:level="1"><nlm:affiliation>I.K. Gujral Punjab Technical University, Kapurthala, Punjab, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>I.K. Gujral Punjab Technical University, Kapurthala, Punjab</wicri:regionArea><wicri:noRegion>Punjab</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Kota College of Pharmacy, Kota, Rajasthan, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Kota College of Pharmacy, Kota, Rajasthan</wicri:regionArea><wicri:noRegion>Rajasthan</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:30124146</idno><idno type="pmid">30124146</idno><idno type="doi">10.2174/1381612824666180820150150</idno><idno type="wicri:Area/Main/Corpus">000717</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000717</idno><idno type="wicri:Area/Main/Curation">000717</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000717</idno><idno type="wicri:Area/Main/Exploration">000717</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Emerging and Alternative Therapies For Parkinson Disease: An Updated Review.</title><author><name sortKey="Kabra, Atul" sort="Kabra, Atul" uniqKey="Kabra A" first="Atul" last="Kabra">Atul Kabra</name><affiliation wicri:level="1"><nlm:affiliation>I.K. Gujral Punjab Technical University, Kapurthala, Punjab, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>I.K. Gujral Punjab Technical University, Kapurthala, Punjab</wicri:regionArea><wicri:noRegion>Punjab</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Kota College of Pharmacy, Kota, Rajasthan, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Kota College of Pharmacy, Kota, Rajasthan</wicri:regionArea><wicri:noRegion>Rajasthan</wicri:noRegion></affiliation></author><author><name sortKey="Sharma, Rohit" sort="Sharma, Rohit" uniqKey="Sharma R" first="Rohit" last="Sharma">Rohit Sharma</name><affiliation wicri:level="1"><nlm:affiliation>Central Ayurveda Research Institute for Drug Development, CCRAS, Ministry of AYUSH, Government of India, Bidhannagar, Kolkata, West Bengal, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Central Ayurveda Research Institute for Drug Development, CCRAS, Ministry of AYUSH, Government of India, Bidhannagar, Kolkata, West Bengal</wicri:regionArea><wicri:noRegion>West Bengal</wicri:noRegion></affiliation></author><author><name sortKey="Kabra, Ruchika" sort="Kabra, Ruchika" uniqKey="Kabra R" first="Ruchika" last="Kabra">Ruchika Kabra</name><affiliation wicri:level="1"><nlm:affiliation>Kota College of Pharmacy, Kota, Rajasthan, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Kota College of Pharmacy, Kota, Rajasthan</wicri:regionArea><wicri:noRegion>Rajasthan</wicri:noRegion></affiliation></author><author><name sortKey="Baghel, Uttam Singh" sort="Baghel, Uttam Singh" uniqKey="Baghel U" first="Uttam Singh" last="Baghel">Uttam Singh Baghel</name><affiliation wicri:level="1"><nlm:affiliation>I.K. Gujral Punjab Technical University, Kapurthala, Punjab, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>I.K. Gujral Punjab Technical University, Kapurthala, Punjab</wicri:regionArea><wicri:noRegion>Punjab</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Kota College of Pharmacy, Kota, Rajasthan, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Kota College of Pharmacy, Kota, Rajasthan</wicri:regionArea><wicri:noRegion>Rajasthan</wicri:noRegion></affiliation></author></analytic><series><title level="j">Current pharmaceutical design</title><idno type="eISSN">1873-4286</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (chemistry)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Complementary Therapies (methods)</term><term>Humans (MeSH)</term><term>Neurosurgical Procedures (MeSH)</term><term>Parkinson Disease (therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiparkinsoniens (composition chimique)</term><term>Antiparkinsoniens (usage thérapeutique)</term><term>Humains (MeSH)</term><term>Maladie de Parkinson (thérapie)</term><term>Procédures de neurochirurgie (MeSH)</term><term>Thérapies complémentaires (méthodes)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="composition chimique" xml:lang="fr"><term>Antiparkinsoniens</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Complementary Therapies</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Thérapies complémentaires</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Maladie de Parkinson</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiparkinsoniens</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Neurosurgical Procedures</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Procédures de neurochirurgie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) is standout amongst the most common neurodegenerative malady with unpredictable dynamic pathology. At present, accessible traditional choices for PD have certain impediments of their own, and subsequently persistent consistence and fulfillment are low. Current contemporary treatment options just give symptomatic alleviation constrained control to anticipate malady progression, bringing about poor patient consistence and fulfilment. Numerous rising pharmacotherapies for PD are in various phases of medical improvement. Treatments incorporate adenosine A2A receptor antagonists, anti-apoptotic agents, monoamine oxidase inhibitors, glutamate receptor antagonists, and antioxidants for example, N-acetyl cysteine, edaravone, and coenzyme Q10. Other rising nonpharmacotherapies incorporate microRNAs, viral vector gene therapy, stem cells transglutaminases, RTP801, and glial derived neurotrophic factor (GDNF). Furthermore, surgeries including profound pallidotomy, deep brain stimulation, thalamotomy and gamma knife surgery have developed as elective mediations for cutting edge PD patients who have totally used common medications and still suffer from unrelenting motor symptoms. Complementary and Alternative medicine (CAM) modalities, such as Yoga, acupuncture, Tai Chi, Music therapies are highly practiced in several countries, offer some of the safer and effective treatment modalities for PD. While a few of these treatments hold much assurance in postponing the beginning of ailment and moderating its progression, more pharmacotherapies and careful mediations should be examined in various phases of PD. Therefore, the main objective of our review is to fill the gap between the researches and provide updated and productive information about the research reported in the last couple of years and can fulfil the most reassuring plausibility for encourage treatment of Parkinson Disease.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30124146</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-4286</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>22</Issue><PubDate><Year>2018</Year></PubDate></JournalIssue><Title>Current pharmaceutical design</Title><ISOAbbreviation>Curr Pharm Des</ISOAbbreviation></Journal><ArticleTitle>Emerging and Alternative Therapies For Parkinson Disease: An Updated Review.</ArticleTitle><Pagination><MedlinePgn>2573-2582</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2174/1381612824666180820150150</ELocationID><Abstract><AbstractText>Parkinson's disease (PD) is standout amongst the most common neurodegenerative malady with unpredictable dynamic pathology. At present, accessible traditional choices for PD have certain impediments of their own, and subsequently persistent consistence and fulfillment are low. Current contemporary treatment options just give symptomatic alleviation constrained control to anticipate malady progression, bringing about poor patient consistence and fulfilment. Numerous rising pharmacotherapies for PD are in various phases of medical improvement. Treatments incorporate adenosine A2A receptor antagonists, anti-apoptotic agents, monoamine oxidase inhibitors, glutamate receptor antagonists, and antioxidants for example, N-acetyl cysteine, edaravone, and coenzyme Q10. Other rising nonpharmacotherapies incorporate microRNAs, viral vector gene therapy, stem cells transglutaminases, RTP801, and glial derived neurotrophic factor (GDNF). Furthermore, surgeries including profound pallidotomy, deep brain stimulation, thalamotomy and gamma knife surgery have developed as elective mediations for cutting edge PD patients who have totally used common medications and still suffer from unrelenting motor symptoms. Complementary and Alternative medicine (CAM) modalities, such as Yoga, acupuncture, Tai Chi, Music therapies are highly practiced in several countries, offer some of the safer and effective treatment modalities for PD. While a few of these treatments hold much assurance in postponing the beginning of ailment and moderating its progression, more pharmacotherapies and careful mediations should be examined in various phases of PD. Therefore, the main objective of our review is to fill the gap between the researches and provide updated and productive information about the research reported in the last couple of years and can fulfil the most reassuring plausibility for encourage treatment of Parkinson Disease.</AbstractText><CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kabra</LastName><ForeName>Atul</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>I.K. Gujral Punjab Technical University, Kapurthala, Punjab, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kota College of Pharmacy, Kota, Rajasthan, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Rohit</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Central Ayurveda Research Institute for Drug Development, CCRAS, Ministry of AYUSH, Government of India, Bidhannagar, Kolkata, West Bengal, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kabra</LastName><ForeName>Ruchika</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Kota College of Pharmacy, Kota, Rajasthan, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baghel</LastName><ForeName>Uttam Singh</ForeName><Initials>US</Initials><AffiliationInfo><Affiliation>I.K. Gujral Punjab Technical University, Kapurthala, Punjab, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kota College of Pharmacy, Kota, Rajasthan, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Pharm Des</MedlineTA><NlmUniqueID>9602487</NlmUniqueID><ISSNLinking>1381-6128</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000529" MajorTopicYN="N">Complementary Therapies</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019635" MajorTopicYN="Y">Neurosurgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Ayurveda</Keyword><Keyword MajorTopicYN="Y">Parkinson disease</Keyword><Keyword MajorTopicYN="Y">alternative medicine</Keyword><Keyword MajorTopicYN="Y">depression</Keyword><Keyword MajorTopicYN="Y">dopamine</Keyword><Keyword MajorTopicYN="Y">pharmacotherapies.</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>06</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>08</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>08</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30124146</ArticleId><ArticleId IdType="pii">CPD-EPUB-92506</ArticleId><ArticleId IdType="doi">10.2174/1381612824666180820150150</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Inde</li></country></list><tree><country name="Inde"><noRegion><name sortKey="Kabra, Atul" sort="Kabra, Atul" uniqKey="Kabra A" first="Atul" last="Kabra">Atul Kabra</name></noRegion><name sortKey="Baghel, Uttam Singh" sort="Baghel, Uttam Singh" uniqKey="Baghel U" first="Uttam Singh" last="Baghel">Uttam Singh Baghel</name><name sortKey="Baghel, Uttam Singh" sort="Baghel, Uttam Singh" uniqKey="Baghel U" first="Uttam Singh" last="Baghel">Uttam Singh Baghel</name><name sortKey="Kabra, Atul" sort="Kabra, Atul" uniqKey="Kabra A" first="Atul" last="Kabra">Atul Kabra</name><name sortKey="Kabra, Ruchika" sort="Kabra, Ruchika" uniqKey="Kabra R" first="Ruchika" last="Kabra">Ruchika Kabra</name><name sortKey="Sharma, Rohit" sort="Sharma, Rohit" uniqKey="Sharma R" first="Rohit" last="Sharma">Rohit Sharma</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SanteMusiqueV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000829 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000829 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SanteMusiqueV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:30124146
|texte= Emerging and Alternative Therapies For Parkinson Disease: An Updated Review.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:30124146" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SanteMusiqueV1
| This area was generated with Dilib version V0.6.38. |  |